Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis
Related Experiment Video
Updated: Apr 11, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Kuttipurath Kandi Roshique1, Vinod Ravindran
1Department of Rheumatology, National Hospital, Calicut, Kerala, India.
Abstract:
Biosimilar usage in rheumatology is set to increase over the next few years. This study reports the efficacy and toxicity of a rituximab biosimilar in biologic naïve patients with active rheumatoid arthritis who had inadequately responded to methotrexate. In 21 patients, over a follow-up period of 36 months, it demonstrated prolonged benefit in a majority (10 in remission with disease activity score 28 (DAS28) erythrocyte sedimentation rate (ESR) <2.6 and 9 in low disease activity state with DAS28 ESR between 3.2 and 2.6) and was well tolerated.
More Related Videos
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management